Committee Action
The Committee on Ways and Means marked up H.R. 8816, the
American Medical Innovation and Investment Act of 2024, on June
27, 2024, and favorably reported the bill, as amended, to the
House of Representatives (with quorum being present).
D. Designated Hearing
Pursuant to clause 3(c)(6) of rule XIII, the following
hearing was used to develop and consider H.R. 8816:
``Hearing on Examining Policies that Inhibit Innovation and
Patient Access'' May 10, 2023.
II. EXPLANATION OF THE BILL
A. Reasons for Change
This legislation encompasses several policies intended to
improve the Medicare benefit. Cognitive testing as included in
the Medicare Annual Wellness Visit does not require specific
tools to be used, meaning testing can fluctuate in
effectiveness.
National Coverage Determinations with Coverage with
Evidence Development protocols are frequently endless coverage
restrictions instead of meaningful coverage processes to
collect evidence, undermining the true intent of the program.
Full National Coverage Determinations can be confusing and
opaque for applicants, with applicants not knowing whether or
not the application is complete or if they are incomplete how
they did not meet the standards required for consideration.
Local Coverage Determinations can exceed federal law or payment
policy in contradiction to the federal code.
External infusion pumps and non-self-administrable home
infusion drugs are more convenient for patients, but Medicare
guidance has not allowed their reimbursement.
Medicare coverage policies for artificial intelligence
powered dosing devices is unclear.
Medicare coverage policies for prescription digital
therapeutics is unclear.
Medically tailored meals can greatly benefit patient
recovery but there is not sufficient data to support full
programmatic changes.
B. Explanation of Provisions
Section 1. Short title
The short title is ``American Medical Innovation and
Investment Act of 2024''.
Section 2. Cognitive Impairment Detection Benefit in the Medicare
Annual Wellness Visit and Initial Preventive Physical
Examination
This provision would require the cognitive impairment test
in the Medicare Annual Wellness Visit to be performed using a
cognitive impairment detection tool identified by the National
Institute on Aging.
Section 3. Improving the National and Local Coverage Determination
Process Under the Medicare Program
This provision would require National Coverage
Determinations (NCDs) with Coverage with Evidence Development
(CEDs) to be reconsidered every 10 years unless it is necessary
for the collection of additional evidence; require Medicare to
notify NCD applicants whether the application is complete or
not within 90 days; and prevent Local Coverage Determinations
(LCDs) from superseding federal law, ruling, regulation, NCD,
payment policy, or coding policy.
Section 4. Medicare Coverage of External Infusion Pumps and Non-Self-
Administrable Home Infusion Drugs
This provision would guarantee coverage of self-
administered home infusion pumps under Medicare by clarifying
the definition of external infusion pumps as ``appropriate for
use in the home'' for certain individuals and educate members
on any cost sharing differential.
Section 5. Guidance on Medicare Payment for Certain Items Involving
Artificial Intelligence
This provision would require Medicare to clarify and update
coverage for AI-enabled dosing devices.
Section 6. Clarifying Payment for Prescription Digital Therapeutics
Under Medicare
This provision would require Medicare to clarify and update
coverage for Prescription Digital Therapeutics.
Section 7. Medically Tailored Home-Delivered Meals Demonstration
Program
This provision would require Medicare to stand up a
demonstration program for medically tailored home-delivered
meals in a budget neutral manner to help seniors improve health
outcomes and reduce readmission rates.
C. Effective Date
Sec. 2 of the bill would become effective January 1, 2025.
Sec. 3 of the bill would become effective upon enactment of
the bill.
Sec. 4 of the bill would become effective upon enactment of
the bill.
Sec. 5 of the bill would become effective January 1, 2026.
Sec. 6 of the bill would become effective January 1, 2026.
Sec. 7 of the bill would become effective January 1, 2025.
III. VOTES OF THE COMMITTEE
In compliance with the Rules of the House of
Representatives, the following statement is made concerning the
vote of the Committee on Ways and Means during the markup
consideration of H.R. 8816, the ``American Medical Innovation
and Investment Act,'' on June 27, 2024.
H.R. 8816 was ordered favorably reported to the House of
Representatives as amended by a roll call vote of 40 yeas to 0
nays (with a quorum being present). The vote was as follows:
----------------------------------------------------------------------------------------------------------------
Representative Yea Nay Present Representative Yea Nay Present
----------------------------------------------------------------------------------------------------------------
Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. X ...... .........
Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... X ...... .........
Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... .........
Mr. Kelly.......................... X ...... ......... Mr. Larson........... X ...... .........
Mr. Schweikert..................... X ...... ......... Mr. Blumenauer....... X ...... .........
Mr. LaHood......................... X ...... ......... Mr. Pascrell......... X ...... .........
Dr. Wenstrup....................... X ...... ......... Mr. Davis............ X ...... .........
Mr. Arrington...................... X ...... ......... Ms. Sanchez.......... X ...... .........
Dr. Ferguson....................... X ...... ......... Ms. Sewell........... X ...... .........
Mr. Estes.......................... ...... ...... ......... Ms. DelBene.......... X ...... .........
Mr. Smucker........................ X ...... ......... Ms. Chu.............. X ...... .........
Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... .........
Ms. Miller......................... X ...... ......... Mr. Kildee........... X ...... .........
Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... .........
Mr. Kustoff........................ X ...... ......... Mr. Evans............ ...... ...... .........
Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ X ...... .........
Mr. Steube......................... X ...... ......... Mr. Panetta.......... X ...... .........
Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... .........
Mrs. Fischbach..................... X ...... .........
Mr. Moore.......................... X ...... .........
Mrs. Steel......................... X ...... .........
Ms. Van Duyne...................... X ...... .........
Mr. Feenstra....................... X ...... .........
Ms. Malliotakis.................... X ...... .........
Mr. Carey.......................... X ...... .........
----------------------------------------------------------------------------------------------------------------
IV. BUDGET EFFECTS OF THE BILL
A. Committee Estimate of Budgetary Effects
In compliance with clause 3(d) of rule XIII of the Rules of
the House of Representatives, the following statement is made
concerning the effects on the budget of the bill, H.R. 8816, as
reported. The estimate prepared by the Congressional Budget
Office (CBO) is included below.
B. Statement Regarding New Budget Authority and
Tax Expenditures Budget Authority
In compliance with clause 3(c)(2) of rule XIII of the Rules
of the House of Representatives, the Committee states that the
bill involved no new or increased budget authority. The
Committee states further that the bill involves no new or
increased tax expenditures.
C. Cost Estimate Prepared by the Congressional
Budget Office
In compliance with clause 3(c)(3) of rule XIII of the Rules
of the House of Representatives, requiring a cost estimate
prepared by the CBO, the following statement by CBO is
provided.
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
Summary of legislation: The House Committee on Ways and
Means marked up a total of 10 bills on May 8, 2024, and on June
27, 2024. This document provides estimates for six of those
bills.
Generally, the bills would:
Modify Medicare's payment policy with
respect to ambulances and hospitals that operate in
rural areas,
Provide Medicare-funded graduate medical
education slots at rural hospitals,
Reinstate nursing certification programs at
facilities that had previously lost the ability to
operate those programs,
Establish a Medicare pilot program to award
grants to rural hospitals,
Revise the definition of ``rural emergency
hospital'' under Medicare, and
Expand Medicare coverage for the home
infusion of drugs.
Estimated Federal cost: Three of the bills would affect
direct spending; the estimated effects are shown in Table 1.
The costs fall within budget function 570 (Medicare).
TABLE 1.--ESTIMATED EFFECTS ON DIRECT SPENDING OF MEDICARE LEGISLATION, AS ORDERED REPORTED BY THE HOUSE COMMITTEE ON WAYS AND MEANS ON MAY 8, 2024, AND
JUNE 27, 2024
--------------------------------------------------------------------------------------------------------------------------------------------------------
By fiscal year, millions of dollars--
---------------------------------------------------------------------------------------------------
2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2025-2029 2025-2034
--------------------------------------------------------------------------------------------------------------------------------------------------------
INCREASES OR DECREASES (-) IN DIRECT SPENDING
H.R. 7931:
Budget Authority................................ 1 3 4 5 6 8 9 11 13 14 19 74
Estimated Outlays............................... 1 3 5 5 6 8 9 11 13 14 19 74
H.R. 8246:
Budget Authority................................ 0 29 117 193 284 336 443 551 651 807 623 3,411
Estimated Outlays............................... 0 29 117 193 284 336 443 551 651 807 623 3,411
H.R. 8816:
Budget Authority................................ 1 -8 -11 -14 -13 -15 -17 -17 -18 -17 -45 -129
Estimated Outlays............................... 1 -8 -11 -14 -12 -15 -17 -18 -18 -17 -45 -129
--------------------------------------------------------------------------------------------------------------------------------------------------------
Components may not sum to totals because of rounding.
Basis of estimate: For this estimate, CBO assumes that each
bill will be enacted in fiscal year 2025.
Direct spending: CBO estimates that enacting H.R. 8235,
H.R. 8244, and H.R. 8245 would have no effect on direct
spending. CBO estimates that enacting the other three of the
six bills would affect direct spending.
H.R. 7931, the Preserving Emergency Access in Key Sites
Act, would increase Medicare payments for certain rural
ambulance suppliers and hospitals. Payments would rise to 101
percent of what is termed reasonable cost, which is greater
than amounts under current law. CBO estimates that enacting the
bill would increase direct spending by $74 million over the
2025-2034 period and that enacting the bill would not affect
revenues.
H.R. 8246, the Second Chances for Rural Hospitals Act,
would allow critical access hospitals and certain small rural
hospitals that closed between January 1, 2014, and December 26,
2020, to reopen as rural emergency hospitals. Those facilities
would qualify for additional Medicare payments, including
higher reimbursement rates and annual facility payments,
depending on their distance from other hospitals. Based on an
assessment of the number of additional locations that would
become eligible for monthly payments, CBO estimates that
enacting the bill would result in about 6,000 additional
monthly payments to rural emergency hospitals, increasing
Medicare fee-for-service spending by $2 billion. That change
also would increase payments to Medicare Advantage plans. CBO
estimates that enacting H.R. 8246 would increase total direct
spending by $3.4 billion over the 2025 2034 period and that
enacting the bill would not affect revenues.
H.R. 8816, the American Medical Innovation and Investment
Act of 2024, would modify rules for determining national and
local coverage in Medicare's programs and revise certain
Medicare payments and benefits. CBO estimates that enacting the
bill would decrease net direct spending by $129 million over
the 2025-2034 period. The bill would provide $5 million to the
Centers for Medicare & Medicaid Services, which CBO estimates
would increase direct spending by the same amount over the
2025-2034 period to implement changes to the national and local
coverage process. The bill also would expand Medicare coverage
for the home infusion of drugs. CBO estimates that enacting
that provision would reduce direct spending by $134 million
over the 2025-2034 period. The bill also would direct the
Department of Health and Human Services to conduct a four-year
demonstration project offering medically tailored, home-
delivered meals to beneficiaries with heart disease, diabetes,
or other conditions. CBO estimates that enacting the medically
tailored meals demonstration would not significantly affect
direct spending over the 2025-2034 period. CBO estimates that
enacting the bill would not affect revenues.
Spending subject to appropriation: CBO has not completed
estimates of spending subject to appropriation for any of the
bills.
Pay-As-You-Go considerations: The Statutory Pay-As-You-Go
Act of 2010 establishes budget-reporting and enforcement
procedures for legislation affecting direct spending or
revenues. The net changes in outlays for the three bills that
are subject to pay-as-you-go procedures are shown in Table 1.
Increase in long-term net direct spending and deficits: CBO
estimates that enacting H.R. 8246 would increase net direct
spending by more than $2.5 billion in at least one of the four
consecutive 10-year periods beginning in 2035. None of the
other bills, if enacted, would do so.
CBO estimates that enacting H.R. 8246 would increase on-
budget deficits by more than $5 billion in at least one of the
four consecutive 10-year periods beginning in 2025. None of the
other bills, if enacted, would do so.
Mandates: The bill contains no intergovernmental or
private-sector mandates as defined in the Unfunded Mandates
Reform Act.
Previous CBO estimate: On March 13, 2024, CBO transmitted a
cost estimate for H.R. 5397, the Joe Fiandra Access to Home
Infusion Act of 2023, as ordered reported by the House
Committee on Energy and Commerce on December 6, 2023. Section 2
of H.R. 5397 is similar to section 4 of H.R. 8816. Both bills
would expand Medicare coverage for the home infusion of drugs.
Estimate prepared by: Federal Costs: Austin Barselau
(Medicare Advantage and Medicare Part D); Cornelia Hall
(Medicare Part B); Hudson Osgood (Medicare Part B); Lara
Robillard (Medicare Part B); Sarah Sajewski (Medicare Part A);
Julia Sheriff (Medicare Part A); Noah Zwiefel (Medicare
Advantage and Medicare Part D). Mandates: Andrew Laughlin.
Estimate reviewed by: Asha Saavoss, Chief, Health Systems
and Medicare Cost Estimates Unit; Kathleen FitzGerald, Chief,
Public and Private Mandates Unit; Chad Chirico, Director of
Budget Analysis.
Estimate approved by: Phillip L. Swagel, Director,
Congressional Budget Office.
V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE
A. Committee Oversight Findings and Recommendations
With respect to clause 3(c)(1) of rule XIII of the Rules of
the House of Representatives, the Committee made findings and
recommendations that are reflected in this report.
B. Statement of General Performance Goals and Objectives
With respect to clause 3(c)(4) of rule XIII of the Rules of
the House of Representatives, the Committee advises that the
bill does not authority funding, so no statement of general
performance goals and objectives is required.
C. Information Relating to Unfunded Mandates
This information is provided in accordance with section 423
of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104-
4).
The Committee has determined that the bill does not contain
Federal mandates on the private sector. The Committee has
determined that the bill does not impose a Federal
intergovernmental mandate on State, local, or tribal
governments.
D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff
Benefits
With respect to clause 9 of rule XXI of the Rules of the
House of Representatives, the Committee has carefully reviewed
the provisions of the bill, and states that the provisions of
the bill do not contain any congressional earmarks, limited tax
benefits, or limited tariff benefits within the meaning of the
rule.
E. Duplication of Federal Programs
In compliance with clause 3(c)(5) of rule XIII of the Rules
of the House of Representatives, the Committee states that no
provision of the bill establishes or reauthorizes: (1) a
program of the Federal Government known to be duplicative of
another Federal program; (2) a program included in any report
from the Government Accountability Office to Congress pursuant
to section 21 of Public Law 111-139; or (3) a program related
to a program identified in the most recent Catalog of Federal
Domestic Assistance, published pursuant to the Federal Program
Information Act (Pub. L. No. 95-220, as amended by Pub. L. No.
98-169).
VI. CHANGES IN EXISTING LAW MADE BY THE BILL,
AS REPORTED
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as